Cost-effectiveness analysis of statins for the treatment of hospitalized COVID-19 patients Journal Article
| Authors: | Chow, R.; Simone, C. B. 2nd; Prsic, E. H.; Shin, H. J. |
| Article Title: | Cost-effectiveness analysis of statins for the treatment of hospitalized COVID-19 patients |
| Abstract: | Background: A recent systematic review and meta-analysis reporting on thirteen published cohorts investigating 110,078 patients demonstrated that patients who were administered statins after their COVID-19 diagnosis and hospitalization were had a lower risk of mortality. While these findings are encouraging, given competing COVID-19 treatment approaches, it is unclear if statin use should be prioritized and if its use is a cost-effective treatment options for hospitalized COVID-19 patients. In this study, we report on a cost-effectiveness analysis of statin-containing treatment regimens for hospitalized COVID-19 patients. Methods: A Markov model was used to compare statin use and no statin use among hospitalized COVID-19 patients from a United States healthcare perspective. The cycle length was one week, with a time horizon of 4 weeks. A Monte Carlo microsimulation with 20,000 samples were used. All analyses were conducted using TreeAge Pro Healthcare Version 2021 R1.1. Results: The mean cost for patients receiving statins in addition to usual care was $31,623 (SD $20,331), whereas the mean cost for patients not receiving statins was $33,218 (SD $25,440). The mean effectiveness for the two cohorts were 1.73 (SD 0.96) and 1.71 (SD 1.00), respectively. Conclusions: This analysis demonstrated that treatment of hospitalized COVID-19 patients with statins was both cheaper and more effective than treatment without statins; statin-containing therapy dominates over non-statin therapy. Statin medications for the treatment of COVID-19 should be further investigated in randomized controlled trials, especially considering its cost-effective nature. Optimistically and pending the results of future randomized trials, statins should be considered for use broadly for the treatment of hospitalized COVID-19 patients. © Annals of Palliative Medicine. All rights reserved. |
| Keywords: | survival; hospitalization; cost-effectiveness analysis; statins; covid-19 |
| Journal Title: | Annals of Palliative Medicine |
| Volume: | 11 |
| Issue: | 7 |
| ISSN: | 2224-5820 |
| Publisher: | AME Publishing Company |
| Date Published: | 2022-07-01 |
| Start Page: | 2285 |
| End Page: | 2290 |
| Language: | English |
| DOI: | 10.21037/apm-21-2797 |
| PUBMED: | 35400155 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 September 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work